Research And Markets: Has The Market For Therapeutic Antibodies Entered A New Era?

MAb therapies brought in revenues of over $5.1 billion in 2003 and will continue to grow at an impressive rate throughout the next five years. Revenues should nearly triple during this time as a result of the launch of a plethora of new MAbs and the approval of new indications for MAbs already on the market. By 2008, MAbs should account for 32 percent of all revenue in the biotech market.

(PRWEB) December 6, 2004 -- MAb therapies brought in revenues of over $5.1 billion in 2003 and will continue to grow at an impressive rate throughout the next five years. Revenues should nearly triple during this time as a result of the launch of a plethora of new MAbs and the approval of new indications for MAbs already on the market. By 2008, MAbs should account for 32 percent of all revenue in the biotech market.

Research and Markets (http://www.researchandmarkets.com/reports/c9913) has announced the addition of Monoclonal Antibody Therapies 2004: Entering a New Competitive Era to their offering.

This new report has been written to provide members of the pharmaceutical, biotech, and venture capital industries an analytically based overview of the market for therapeutic monoclonal antibodies (MAbs).

The market for therapeutic antibodies has indeed entered a new era. The success of such therapies as Remicade and Rituxan has paved the way for a whole new crop of antibody therapies that are being developed for autoimmune disease, cancer, and other diseases.

Monoclonal Antibody Therapies 2004 includes the following features:

- Thorough market analysis of global monoclonal antibody sales, segmented by product, company, and geographic region

- Financial forecasts for key MAbs on the market as well as promising new MAbs entering the market

- Analysis of MAb manufacturing issues and their effect on the financial potential of the therapeutic MAb market

- Profiles of key companies involved in the development and marketing of therapeutic MAbs

- A review of important happenings in R&D and an evaluation of the upcoming crop of new MAbs

- Profiles of companies making an impact in the field, with details of licensing deals and collaborations.

The contents of this report are as follows:

1 Introduction and Methodology
2 The Science of Monoclonal Antibodies: An Overview
3 Therapeutic Applications for Monoclonal Antibodies
4 Market Analysis
5 The State of MAb Manufacturing Capacity
6 The Future of the Monoclonal Antibody Market: Financial Forecast and
Industry Trends 2004-2008
7 Research and Development
8 Key Company Profiles and Collaborations
Abbott Laboratories
Collaborative Efforts
Abgenix
Collaborations with Amgen
Antisoma
Biogen Idec
Table 8.1 Biogen Idec's Monoclonal Antibody Pipeline Collaborative Efforts
Cambridge Antibody Technology
CAT's Collaborative Experience
Celltech Group
Genentech
Genentech's Pipeline
The Roche Connection
Other Important Collaborations
Genmab
Key Alliances
ImClone Systems
Centocor (Johnson & Johnson)
Medarex
MedImmune
Protein Design Labs
PDL's Antibody Alliances
Seattle Genetics
Key Alliances
Xoma
A Collaborative Business Model at Work

Tables and Graphs
Appendices

For more information visit http://www.researchandmarkets.com/reports/c9913

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

###